On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.

Sailer, Verena; Pauli, Chantal; Merzier, Elyze C; Mosquera, Juan Miguel; Beltran, Himisha; Rubin, Mark Andrew; Rao, Rema A (2017). On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. Anticancer research, 37(4), pp. 1569-1573. International Inst. of Anticancer Research 10.21873/anticanres.11486

[img] Text
1569.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (277kB) | Request a copy

BACKGROUND/AIM Development of patient-derived three-dimensional (3D) organoid cultures is an emerging technique in the field of precision oncology. We aimed to integrate on-site adequacy evaluation using cytology into the tumor organoid development workflow to ensure precise characterization and growth of these cultures. PATIENTS AND METHODS Cancer patients were consented to a Precision Medicine trial. Fresh tissue was procured for genomic analyses as well as organoid development. Fresh tissue destined for organoid development was evaluated by preparing on-site cytology smears to ensure that only lesional tissue would be submitted for further cell culture work. RESULTS Cytology preparations were made from 64 different tumor samples and evaluated prior to tissue submission for organoid development. In 53 (82.2%) of those tumor samples, the cytology preparation was diagnostic, thus providing adequate material for organoid development. CONCLUSION Characterizing the tissue prior to submission for organoid development ensures submission of lesional tissue only. Furthermore, it is a cost-effective method that can help document patient diagnosis. This can be of importance in biopsies, since the tissue submitted for organoid development cannot be retrieved for clinical diagnosis afterwards. Our findings in this pilot study led to the implementation of on-site cytological evaluation in the tumor organoid development workflow at the Englander Institute for Precision Medicine, NY, USA.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

UniBE Contributor:

Rubin, Mark Andrew

Subjects:

500 Science
500 Science > 570 Life sciences; biology

ISSN:

0250-7005

Publisher:

International Inst. of Anticancer Research

Language:

English

Submitter:

Marla Rittiner

Date Deposited:

08 Mar 2018 14:18

Last Modified:

03 Nov 2019 18:26

Publisher DOI:

10.21873/anticanres.11486

PubMed ID:

28373416

Uncontrolled Keywords:

DNA sequencing Precision medicine cytology drug screening organoids

BORIS DOI:

10.7892/boris.110866

URI:

https://boris.unibe.ch/id/eprint/110866

Actions (login required)

Edit item Edit item
Provide Feedback